Clinical Trials & Results

Search or filter the listing below to find a trial or results of a completed trial.

View Actively Recruiting Clinical Trials

Click here to see trials currently recruiting participants

Filter

Health Condition

Toggle

Study Status

Toggle

Age group

Toggle

Gender

Toggle

Phase

Toggle

Study Types

Toggle

All Results

No results found

Please change the filter settings to find the product(s) you are looking for. You can also use the search function to look up a product.

Clear Filters

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years to 50 Years
Interventions:
Drug: laquinimod 0.3 | Drug: laquinimod 0.6 | Other: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate Compared to Placebo

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years to 55 Years
Interventions:
Drug: Glatiramer acetate (GA) | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Comparing Two Doses of Glatiramer Acetate

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years to 55 Years
Interventions:
Drug: Glatiramer Acetate (GA) 40 mg | Drug: glatiramer acetate 20 mg
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Disease Progression Study for the Treatment of RRMS

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Terminated
Requirements:
18 Years to 50 Years
Interventions:
Drug: Glatiramer Acetate | Drug: Betaseron | Drug: Rebif
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Exploring the Long Term Safety, Tolerability and Clinical Effect of Laquinimod

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Terminated
Requirements:
18 Years to 50 Years
Interventions:
Drug: Laquinimod | Drug: Placebo
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for MS

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
20 Years to 57 Years
Interventions:
Drug: Copaxoneֲ®
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Safety and Effectiveness of Novantrone Therapy Followed by Copaxone

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years to 55 Years
Interventions:
Drug: glatiramer acetate 20 mg | Drug: glatiramer acetate 20 mg, with mitoxantrone
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Safety of New Formulation of Glatiramer Acetate (Song)

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Completed
Requirements:
18 Years and older
Interventions:
Drug: Glatiramer Acetate | Drug: Experimental Glatiramer Acetate
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Terminated
Requirements:
18 Years to 55 Years
Interventions:
Drug: Glatiramer Acetate | Drug: Placebo | Drug: Prednisone
Learn more Please refer to ClinicalTrials.gov for a description of the trial

Study to Evaluate Laquinimod Compared to Interferon ß-1a Administered by Injection

brain-icon.png
Condition(s):
Relapsing Remitting Multiple Sclerosis
Status:
Withdrawn
Requirements:
18 Years to 55 Years
Interventions:
Drug: Laquinimod | Drug: Avonexֲ®
Learn more Please refer to ClinicalTrials.gov for a description of the trial